PMC3420791_01
Well circumscribed subcutaneous tumor mass (HE, x40).
CRIM.PATHOLOGY2012-408575.001.jpg
PMC3420791_01_CRIM.PATHOLOGY2012-408575.001.jpg
fig1
Microscopic examination revealed a subcutaneous well-circumscribed mass, consisting of both cellular areas with especially oval-round-to-spindle-shaped cells intermixed with floret like giant cells in a patternless pattern and hypocellular areas together (Figures 1, 2, and 3).
Admixture of hypocellular and hypercellular areas (HE, x100).
CRIM.PATHOLOGY2012-408575.002.jpg
PMC3420791_01_CRIM.PATHOLOGY2012-408575.002.jpg
fig2
Microscopic examination revealed a subcutaneous well-circumscribed mass, consisting of both cellular areas with especially oval-round-to-spindle-shaped cells intermixed with floret like giant cells in a patternless pattern and hypocellular areas together (Figures 1, 2, and 3). The number of mitotic figures was 2 per 10 HPFs.
Patternless giant cell and spindle cell proliferation (HE, x100).
CRIM.PATHOLOGY2012-408575.003.jpg
PMC3420791_01_CRIM.PATHOLOGY2012-408575.003.jpg
fig3
Microscopic examination revealed a subcutaneous well-circumscribed mass, consisting of both cellular areas with especially oval-round-to-spindle-shaped cells intermixed with floret like giant cells in a patternless pattern and hypocellular areas together (Figures 1, 2, and 3).
Prominent perivascular hyalinization (HE, x100).
CRIM.PATHOLOGY2012-408575.004.jpg
PMC3420791_01_CRIM.PATHOLOGY2012-408575.004.jpg
fig4
The lesion was highly vascularized with varying caliber of blood vessels and involved perivascular hyalinization (Figure 4).
Diffuse CD34 positivity in tumor cells (DAB, x100).
CRIM.PATHOLOGY2012-408575.005.jpg
PMC3420791_01_CRIM.PATHOLOGY2012-408575.005.jpg
fig5
Immunohistochemistry showed strong CD34 (Figure 5), bcl-2 (Figure 6), vimentin reactivity and focal CD99 positivity.
Bcl2 positivity in tumor cells (DAB, x100).
CRIM.PATHOLOGY2012-408575.006.jpg
PMC3420791_01_CRIM.PATHOLOGY2012-408575.006.jpg
fig6
Immunohistochemistry showed strong CD34 (Figure 5), bcl-2 (Figure 6), vimentin reactivity and focal CD99 positivity.